A new once-a-day pill could reverse cognitive decline in Alzheimer’s patients, a clinical trial has shown. 

Tazbentetol, developed by biopharmaceutical company Spinogenix, demonstrated rapid, sustained cognitive improvement in a Phase IIa trial. The randomised, double-blind, placebo-controlled trial enrolled 24 patients in Australia, with Tazbentetol proving to be a safe and effective drug with cognitive improvement increasing over time. 

Tazbentetol has been developed as a regenerative treatment for neurodegenerative and neuropsychiatric diseases with the ability to restore synapses. This helps restore connections between neurons, allowing people to think, plan, remember and control movement.  

The preliminary evidence of the synaptic regenerative activity of Tazbentetol represents a first-in-class approach to treating neurodegenerative diseases and has the potential to reverse declines in cognitive, respiratory and motor function.  

“We are highly encouraged by these results, which show the potential impact that a synaptic regenerative therapy can play in helping restore cognitive function in those with Alzheimer’s disease,” said Dr Stella Sarraf, Chief Executive Officer and Founder of Spinogenix.  

“With our Investigation New Drug cleared in the US, we are looking forward to continuing global development of this first-in-class, and potentially transformative investigational treatment.” 

“This Phase IIa study of Tazbentetol shows encouraging results for synaptic regeneration as a new treatment paradigm in Alzheimer’s,” added Professor Bruce Brew, Neurologist and Principal Investigator at St Vincent’s Hospital in Sydney, Australia.  

“These results show Tazbentetol’s early potential to deliver rapid and sustained cognitive improvement as measured by SMMSE and CDR-SB. The study’s quantitative and qualitative measurements reinforce the importance of reversing synapse losses as a new treatment paradigm that could be initiated following a routine cognitive assessment.” 

Alzheimer’s disease remains the most common cause of dementia, accounting for 60-70% of cases worldwide. 

 

Bruno Quinney, Content Team, DDW